The FDA Just Rewrote a Warning Label 20+ Years in the Making

I get some version of this question almost every week, from women in their late 40s through their 60s: "Is hormone therapy actually safe, or am I just going to end up in the group of people who wishes they hadn't?"

For over two decades, the honest answer had an asterisk on it. That asterisk just got smaller.

What happened. In November of last year, the FDA announced it was removing the black box warning — the strongest warning the agency issues — from menopausal hormone therapy, including bioidentical progesterone. By February, product labels for common prescriptions had been updated to reflect it. If you haven't heard about this, you're not alone. It didn't make many headlines, but it's one of the more consequential shifts in women's health policy in years.

Why the warning existed in the first place. It traces back to the Women's Health Initiative (WHI) trial in 2002 — a study that, for a long time, shaped how both doctors and patients thought about hormone therapy, and not always accurately. The warning that followed was applied broadly, across products that weren't chemically identical to each other and didn't carry the same risks. Bioidentical progesterone — a molecule structurally identical to what your body already produces — ended up carrying the same black-box label as synthetic progestins, which are chemically different compounds, often altered specifically so they can be patented.

So what does "bioidentical" actually mean? It's not a marketing term. It refers to a hormone with the exact same molecular structure as the one your body makes — metabolized the way your body already knows how to metabolize it. Synthetic versions are built differently, which changes how they behave and, in some cases, what risks they carry. That distinction matters enormously, and for years the label didn't reflect it.

What the newer research actually shows. More recent analyses have found that risk depends heavily on whichhormone, what form, what dose, and when therapy starts relative to menopause — not a blanket "hormones equal risk." Progestins have been associated with increased breast cancer risk in some studies; bioidentical progesterone has not shown that same association. That's a meaningful difference to have buried under one label for twenty years.

What this means for you: if hormone therapy is something you've considered and dismissed — because of something you read years ago, or a warning label that scared you off before you got the full picture — this is worth a second look with current, accurate information. Not because hormone therapy is right for everyone (it isn't), but because the conversation deserves to start from where the science actually is now, not where it was in 2002.

At ERAs, hormone health is never a one-size-fits-all conversation. It starts with real labs, a real history, and an honest look at whether therapy makes sense for your physiology — not a protocol pulled off a shelf.

If this is something you've been curious about, or dismissed a long time ago, book a visit. I'm always glad to talk it through.

— Dr. Jennifer Hwang

Longevity, on your own terms.